The IBT Connection Study
To evaluate the efficacy of IBP-9414 (study drug) vs. placebo on the prevention of necrotizing enterocolitis (NEC) and on sustained feeding tolerance in very low birth weight premature infants, as well as the safety of IBP-9414 (study drug) vs. placebo.
This research study is led by Rachana Singh, MD, MS.
July 01, 2019
Baystate Medical Center, 759 Chestnut St, Springfield, MA
Gestational age at birth of 23 weeks +0 days -32 weeks +0 days. Birth weight 500-1500g.
The study will end when the patient is discharged from the hospital and has completed GA week 40 follow up visit/call.